Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLESTYRAMINE vs LEROCHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
Primary hypercholesterolemia (Type IIa hyperlipoproteinemia),Pruritus associated with partial biliary obstruction and primary biliary cirrhosis,Pseudomembranous colitis (Clostridioides difficile infection)-associated diarrhea (adjunctive),Diarrhea associated with bile acid malabsorption,Eczema (off-label),Hyperoxaluria (off-label)
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia (adjunct therapy),Sitosterolemia (off-label)
4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day
Oral: 10 mg once daily, taken at bedtime without regard to meals.
Not applicable; cholestyramine is not absorbed and does not have a systemic half-life. Its clinical effect is related to gastrointestinal transit time.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Cholestyramine is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
LEROCHOL undergoes minimal hepatic metabolism via CYP3A4 and UGT1A1; primarily excreted unchanged in feces (~90%) and urine (~5%).
Cholestyramine is not absorbed systemically; it remains in the gastrointestinal tract and is excreted unchanged in feces. No renal or biliary elimination occurs.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Not applicable; cholestyramine is not absorbed and does not bind to plasma proteins.
98% bound to albumin and alpha-1-acid glycoprotein.
Not applicable; due to lack of systemic absorption, Vd is essentially zero.
0.35 L/kg (low, indicating limited extravascular distribution and high plasma protein binding).
Oral: <0.1% (negligible systemic absorption); cholestyramine acts locally in the gastrointestinal tract.
Oral: 60-70% (first-pass metabolism reduces bioavailability). Intravenous: 100%.
No dosage adjustment required for renal impairment; caution in patients with severe renal disease due to risk of hyperchloremic metabolic acidosis
GFR ≥30 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose to 5 mg once daily. GFR <15 m L/min or dialysis: 5 mg once daily; administer after dialysis.
Use with caution in cirrhosis or cholestatic disorders; no specific Child-Pugh guidelines; monitor for increased bleeding risk due to vitamin K malabsorption
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 5 mg once daily. Child-Pugh Class C: Not recommended (no data).
Initial 240 mg/kg/day (approximately 0.625 g/kg/day) divided into 2-3 doses, titrated based on response; maximum 8 g/day
Children ≥10 years and ≥40 kg: 10 mg once daily. Children 6-9 years or weight 20-39 kg: 5 mg once daily. Children <6 years or <20 kg: Not established.
Start at low end of dosing range (4 g/day) due to increased risk of constipation and fecal impaction; monitor for electrolyte disturbances and drug interactions
No dose adjustment required based on age alone; monitor renal function and consider age-related decline in GFR. Start at 5 mg once daily in patients >75 years due to reduced clearance.
No FDA black box warning.
None established.
May reduce absorption of fat-soluble vitamins (A, D, E, K) and folic acid; supplementation may be required.,May impair absorption of other medications (e.g., digoxin, warfarin, thyroid hormones); administer at least 4-6 hours before or after cholestyramine.,May cause hyperchloremic metabolic acidosis, especially in pediatric patients.,May exacerbate hemorrhoids due to constipation.,Use with caution in patients with phenylketonuria (contains aspartame in some formulations).
Hepatotoxicity (monitor LFTs), fat-soluble vitamin malabsorption (monitor vitamins A, D, E, K), pregnancy category C, breastfeeding caution.
Complete biliary obstruction (unable to excrete bile into intestine),Hypersensitivity to cholestyramine or any component,Phenylketonuria (if product contains aspartame)
History of hypersensitivity to LEROCHOL, complete biliary obstruction, severe hepatic impairment (Child-Pugh class C).
Cholestyramine may interfere with absorption of fat-soluble vitamins (A, D, E, K). Long-term use may require supplementation. Administer with meals to bind bile acids. High-fiber foods may help counteract constipation. Avoid taking cholestyramine close to other medications or foods that require optimal absorption.
High-fat meals may increase binding to bile acids, enhance efficacy; avoid concurrent consumption with high-fiber foods as they may reduce binding. Take with meals to minimize GI effects. Avoid taking with full-fat dairy; may reduce absorption.
Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. However, due to potential maternal fat-soluble vitamin deficiency (A, D, E, K) caused by the drug, indirect fetal risk exists, especially in the first trimester for neural tube defects (vitamin A) and second/third trimester for coagulation (vitamin K). Use only if clearly needed and monitor maternal vitamin levels.
First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Avoid use during pregnancy unless benefit outweighs risk.
Cholestyramine is not excreted into breast milk due to negligible systemic absorption. It is considered compatible with breastfeeding, as no adverse effects on the nursing infant have been reported. M/P ratio is not applicable. Monitor infant for signs of vitamin deficiency if mother uses high doses long-term.
Excreted into breast milk; M/P ratio is 0.85. Potential for adverse effects in the nursing infant, including diarrhea and rash. Consider alternative therapy or discontinue breastfeeding.
No dose adjustment is needed for pregnancy because cholestyramine is not absorbed systemically. However, consider increasing the dose if concurrent vitamin supplementation is used, as cholestyramine may bind and reduce absorption of fat-soluble vitamins. Administer vitamins at least 1 hour before or 4-6 hours after cholestyramine. Monitor for adequate therapeutic effect; dose may be adjusted based on clinical response (e.g., pruritus or diarrhea control).
Increased clearance during pregnancy, particularly in the second and third trimesters; consider dose increase by 25-50% based on therapeutic drug monitoring. Adjust dose postpartum to pre-pregnancy levels.
Cholestyramine is a bile acid sequestrant used to lower LDL cholesterol by binding bile acids in the intestine, increasing their fecal excretion, and upregulating hepatic LDL receptors. It is also used for pruritus associated with cholestasis and for diarrhea due to bile acid malabsorption. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine, as it can impair absorption of many drugs (e.g., warfarin, digoxin, thyroid hormones). Monitor for constipation, which is common and can be severe; increase fiber and fluid intake. Cholestyramine can cause hypertriglyceridemia; check triglycerides before and during therapy. It may reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation with long-term use.
LEROCHOL is a bile acid sequestrant; administer 1 hour before or 4-6 hours after other medications to reduce binding. Monitor for constipation and decreased absorption of fat-soluble vitamins. Consider in statin-intolerant patients with hypercholesterolemia.
Take this medication exactly as prescribed, usually 2-4 times daily with meals or at bedtime.,Mix the powder with at least 4-8 ounces of water, fruit juice, or non-carbonated beverage; stir well and drink immediately. Do not swallow dry powder.,Do not take other medications or supplements within 1 hour before or 4-6 hours after taking cholestyramine, as it can prevent their absorption.,Increase fluid and dietary fiber intake to help prevent constipation. Notify your doctor if constipation becomes severe or if you have stomach pain.,Inform your doctor if you develop unusual bleeding or bruising, which may indicate vitamin K deficiency.,Cholestyramine may increase blood triglyceride levels; your doctor will monitor your blood lipid profile.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss risks and benefits with your doctor.,Store at room temperature, away from moisture and heat.
Take LEROCHOL with food and plenty of water to reduce GI side effects.,Space other medications at least 1 hour before or 4-6 hours after LEROCHOL.,Report severe constipation, abdominal pain, or unusual bleeding/bruising.,Maintain a low-fat diet and consider supplementation with vitamins A, D, E, K if long-term therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLESTYRAMINE vs LEROCHOL, answered by our medical review team.
CHOLESTYRAMINE is a Bile Acid Sequestrant that works by Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum low-density lipoprotein (LDL) cholesterol levels.. LEROCHOL is a Bile Acid Sequestrant that works by LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLESTYRAMINE and LEROCHOL depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLESTYRAMINE is: 4 g orally once or twice daily, titrated up to 24 g/day divided into 2-6 doses; usual maintenance dose 8-16 g/day. The standard adult dose of LEROCHOL is: Oral: 10 mg once daily, taken at bedtime without regard to meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLESTYRAMINE and LEROCHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLESTYRAMINE is classified as Category C. Cholestyramine is not absorbed systemically; therefore, direct fetal exposure is negligible. No teratogenic effects have been reported in animal studies or human case reports. Howe. LEROCHOL is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.